Search Results

Onconova Therapeutics, Inc., and Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction.

Onconova Therapeutics, Inc. today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting.

Onconova Therapeutics, Inc. announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.

Onconova Therapeutics, Inc. today announced preclinical data, highlighting narazaciclib’s preclinical activity in Bruton’s kinase inhibitor (BTKi)-resistant mantle cell lymphoma (MCL).

Onconova Therapeutics, Inc. today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors, in a poster presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial results and provided an update on recent pipeline progress.

Onconova Therapeutics, Inc. announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer, and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development.